Pregnancy, lactation, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
The recommended daily intake of calcium and vitamin D during pregnancy is approximately 1000 mg of calcium and approximately 600 IU of vitamin D (15 µg of colecalciferol). Therefore, Ideos Forte is not recommended during pregnancy and lactation, unless your doctor has diagnosed a combined deficiency of calcium and vitamin D.
During pregnancy, the total daily intake of calcium should not exceed 2500 mg and the total daily intake of vitamin D3 should not exceed 4000 IU (100 µg of colecalciferol).
High levels of vitamin D during pregnancy should be avoided, as prolonged high levels of calcium in the blood can cause physical and mental retardation, as well as cardiac and ocular disorders in the child.
Lactation
Ideos Forte can be used during lactation if your doctor has diagnosed a combined deficiency of calcium and vitamin D. Calcium and vitamin D and their metabolites pass into breast milk, which should also be taken into account if your child receives additional vitamin D.
Driving and operating machinery
Ideos Forte does not affect your ability to drive and operate machinery.
Ideos Forte
sorbitol, 185 mg of isomaltase (E-953), and 1.9 mg of sucrose.
If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication may cause tooth decay.
This medication contains less than 1 mmol of sodium (23 mg) per chewable tablet, which is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Dose
Unless your doctor tells you otherwise, the recommended dose is:
Adults and elderly people: 1 chewable tablet per day (corresponding to 500 mg of calcium and 1000 IU [International Units] of vitamin D3).
Administration Form
The tablet must be chewed before swallowing. It can be taken at any time, with or without food.
Pay attention to a daily sufficient intake of calcium through nutrition (for example, dairy products, vegetables, mineral water).
Treatment Duration
Ideos Forte should be taken as a prolonged treatment. Talk to your doctor about the duration of treatment with this medication (see also section 2, Warnings and Precautions).
If you take more Ideos Forte than you should
A overdose of Ideos Forte may produce symptoms such as nausea, vomiting, thirst or excessive thirst, increased urine output, decreased body fluids or constipation.
In case of overdose or accidental ingestion, go to a medical center or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used.
If you forget to take Ideos Forte
If you forget to take Ideos Forte, take it as soon as you remember. However, do not take a double dose to compensate for the missed doses.
If you interrupt the Ideos Forte treatment
If you want to interrupt or prematurely suspend treatment, consult your doctor.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Stop taking Ideos Forte and contact a doctor immediatelyif you experience the following allergic reactions(unknown frequency - cannot be estimated from available data):
Other reported adverse effects are:
Rare:
Skin rash, itching, urticaria.
(Rare adverse effects may affect up to 1 in 1,000 people)
Uncommon:
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through theSpanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.
By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the laminated aluminum. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30?°C.
If your doctor interrupts treatment, do not store any remaining capsules unless the doctor instructs you otherwise. Medications should not be disposed of through drains or in the trash. Dispose of containers and medications you no longer need at theSIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Ideos Forte
-The active principles are calcium and colecalciferol. Each chewable tablet contains 500 mg of calcium (as calcium carbonate) and 25 micrograms of colecalciferol (vitamin D3, equivalent to 1000 UI), in the form of a concentrated colecalciferol powder (in the form of a powder).
-The other components are: isomaltose (E953), xylitol, sorbitol (E420), anhydrous citric acid, sodium citrate dihydrate, magnesium stearate, sodium carmellose, orange aroma “CPB”, orange aroma “CVT”, hydrated colloidal silica, aspartame (E951), potassium acesulfame, sodium ascorbate, all-rac-alpha-tocopherol, modified cornstarch, sucrose, medium-chain triglycerides, and colloidal silicon dioxide.
Appearance of the product and contents of the packaging
IdeosForteare round and white tablets.
The chewable tablets are presented in laminated aluminum strips in the following packaging sizes:
30 or 90 chewable tablets.
Only some packaging sizes may be commercially available.
Holder of the marketing authorization and responsible manufacturer
Holder of the marketing authorization
Theramex Ireland Limited
3rd Floor, Kilmore House,
Park Lane, Spencer Dock,
Dublin 1
D01 YE64
Responsible manufacturer
HERMESPHARMAGmbH
Georg-Kalb-Straße 5
82049 Pullach i. Isartal
Germany
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization:
Theramex Heathcare Spain, S.L.
Calle Martínez Villergas 52, Edificio C, 2nd floor left.
28027 Madrid
Spain
Last review date of this leaflet: October 2023
The detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.